Unicycive Therapeutics, Inc. (UNCY): auditor change — Unicycive Therapeutics appoints Grassi & Co. as new auditor effective Aug 28, 2023

Unicycive Therapeutics, Inc.

Grassi & Co. CPAs, P.C. appointed as independent registered public accounting firm on Aug 28, 2023, subject to client acceptance.
Appointment follows resignation of prior auditor Mayer Hoffman McCann P.C., disclosed on July 31, 2023.
No prior consultations with Grassi on accounting principles or audit opinions during 2022 or through June 30, 2023.
No disagreements or reportable events occurred between company and previous auditor.
Audit Committee approved the appointment.

item 4.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Unicycive Therapeutics, Inc. engaged Grassi & Co. CPAs, P.C. as its auditor.

Action: engagement
Auditor: Grassi & Co. CPAs, P.C.

Exact text from the filing

ugust 28, 2023, the Company appointed Grassi & Co. CPAs, P.C. (“ Grassi ”) as the Company’s new independent registered public accounting firm effective as of August 28, 2023, subject to Grassi’s completion of its client acceptance process. The Audit Committee of the board of directors of the Company approved the appointment of Grassi. During the fiscal year ended December 31, 2022 and the interim period from January 1, 2023 through June 30, 2023, neither the Company, nor anyone

View on SEC.gov

46 auditor changes filed in the last 30 days. Browse all auditor changes →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-072838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.